三维适形放疗加希罗达对晚期胰腺癌止痛效果的研究  被引量:1

EFFICACY OF THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY COMBINED WITH XELODA FOR THE PAIN RELIEF OF ADVANCE PANCRATIC CARCINOMA

在线阅读下载全文

作  者:房彤[1] 陈力[1] 孙保锦[1] 高宏[1] 

机构地区:[1]北京世纪坛医院放疗科,北京100038

出  处:《中国疼痛医学杂志》2007年第5期277-279,共3页Chinese Journal of Pain Medicine

摘  要:目的:观察三维适形放疗联合希罗达同步治疗中晚期胰腺癌疼痛的疗效。方法:28例中晚期胰腺癌患者随机分为两组,综合组14例,采用三维适形放疗的同时给予希罗达同步化疗。放疗开始的第1d开始口服希罗达,每日1000mg/m2,bid.连用14d,停药7d,21d为一周期,至少用药2个周期以上。单放组14例,单独应用三维适形放疗。两组病人照射剂量相同(45~56Gy,1.8~2Gy/次,5次/周)。结果:综合组和单放组疼痛缓解率分别为85.7%、42.9%,疼痛改善持续时间分别为137d、102d。两组疼痛缓解率和疼痛改善持续时间有统计学差异(P〈0.05)。中位生存期综合组(6.8个月)较单放组(4.7个月)延长(P〈0.05)。结论:三维适形放疗联合希罗达可以改善晚期胰腺癌疼痛症状,延长生存期。希罗达可能有放射增敏作用。To observe the clinical efficacy CRT)combined with xeloda for pain relief of advanced pancreatic carcinoma were randomized into two groups: of three-dimensional conformal radiotherapy ( 3 D- pancreatic carcinoma. Methods: 28 patients with combined group, on the basis of 3D-CRT, 14 pa- tients received oral Xeloda at 1000 mg/m2, twicedaily for 14 days followed by 7-day rest period and repeated in every three week intervals for more than two cycles; control group, 14 patients received 3D- CRT alone. Radiation given was similar in the two groups of patient (45 - 56 Gy, 1.8 - 2.0 Gy/f, 5 f/ w). Results : The pain remission rate in combined group and control group were 85.7% and 42.9% respectively. The median time of remission in combined group and control group were 137 d, 102 d respectively. Both remission rate and period of abdominal pain showed significant difference between the two groups ( P 〈 0.05 ). The median survival time were 6.8 months and 4.7 months respectively ( P 〈 0. 05 ). Conclusion: 3D-CRT combined with xeloda for treatment of advanced pancreatic carcinoma may relieve pain and prolong survival time. Xeloda may have radiosensitization.

关 键 词:胰腺癌 三维适形放疗 希罗达 疼痛 

分 类 号:R735.9[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象